NEWS ON THE NON ALCOHOLIC STEATOHEPATITIS DISEASE, ACTORS AND FUTURES TREATMENTS  




Click on the picture details to enter or use the  upper menu



LAST NEWS

2017-10-05 : Galmed Pharmaceuticals Announces Publication of Data on Aramchol™ Mechanism of Action in Hepatology Communications. Data Will Also Be Presented at AASLD

2017-10-01 : Comparative metabolic and hepatic effects of liraglutide, elafibranor and obeticholic acid in diet- induced and genetically obese mouse models of biopsy-confirmed NASH

2017-09-26 : Intercept Pharmaceuticals Inc said OCALIVA could carry a BOXED WARNING ! but no restrictions

2017-09-25 : Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients

2017-09-22 : New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial

2017-09-21 : FDA SAFETY ALERT ON OCALIVA IN PBC WILL UNDOUBTEDLY IMPACT NASH

2017-09-20 : FDA Issues Warning on Liver Injury from Intercept Pharma's (ICPT) Ocaliva

2017-09-18 : Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)

2017-09-12 : IMPORTANT PRESCRIBING INFORMATION SUBJECT: Liver injury, liver decompensation, liver failure, and death have been reported in primary biliary cholangitis (PBC) patients with moderate or severe hepatic impairment (Child-Pugh B and C) when OCALIVA® was dosed more frequently than recommended

2017-09-11 : Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)

2017-09-06 : Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH

2017-09-05 : Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B

2017-09-04 : Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis

2017-08-28 : Study Offers New Targets for Drugs Against Fatty Liver Disease and Liver Cancer

2017-08-19 : SEMAGLUTIDE PERSPECTIVES IN NASH

2017-08-16 : NASH Summit Europe 10-12 October, 2017 Frankfurt, Germany is Europe’s definitive forum which exists to solve the challenges drug developers face from discovery to late stage clinical development.

2017-08-14 : Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

2017-08-01 : Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH

2017-06-23 : GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH

2017-06-20 : Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

2017-06-12 : Regulus hit as AstraZeneca hands back rights to one drug, R&D revamp culls two more

2017-06-08 : Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH

2017-06-05 : Non-alcoholic steatohepatitis (NASH); metabolic syndrome Patient sample, mouse and non-human primate (NHP) studies suggest that enhancing TMBIM1 expression could help treat non-alcoholic steatohepatitis (NASH) and metabolic syndrome

2017-06-02 : New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017

2017-06-01 : GENFIT: Positive Outcome from the 1-year Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor

2017-06-01 : On May26, 2017, the Data and Safety Monitoring Committee (the DSMC) for clinical studies of Madrigal Pharmaceuticals,Inc.'s (the Company) MGL-3196, for the treatment of non-alcoholic steatohepatitis, held a pre-scheduled meeting to review data from the Company's Phase 2 clinical NASH trial.

2017-05-11 : Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)

2017-05-03 : Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH

2017-04-24 : GENFIT : the recruitment of the 1000 first patients of RESOLV'IT will be delayed to T1 2018

2017-04-23 : NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

2017-04-21 : Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

2017-04-20 : Cerenis Therapeutics Announces the Initiation of the Phase 1 Clinical Study with CER-209 in NAFLD and NASH

2017-04-19 : Novartis joins forces with Allergan, pushing a NASH combo into late-stage development

2017-03-29 : Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis

2017-03-28 : GENFIT to host a series of KOL Meetings in NASH

2017-03-02 : RUMOR NOVARTIS COULD BE INTERESTED BY GENFIT

2017-02-28 : Cempra\'s solithromycin fails to match standard of care in GC study, development in NASH suspended

2017-02-17 : CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

2017-02-10 : The 10 of february, 2017 INTERCEPT Announced a modification of the protocole and endpoints, theu say it was done with the endorsement of the FDA and will increase their chance of success, ate this time we do not know the changes in detail . if the reversion definition vas modified to fulfill with the one used by GENFIT , it id definitively not a good news for OCALIVA, they never reached it in the previous studies.

2017-02-06 : Immuron enrols first patient in paediatric fatty liver trial in the U.S.

2017-02-02 : Inventiva launches its initial public offering on the regulated market of Euronext Paris

2017-01-24 : TOBIRA-ALLERGAN- launch STELLARIS: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

2017-01-09 : Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017

2017-01-09 : Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study

2017-01-09 : Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical StudyCompany Plans to Launch a Clinical Development Program in NAFLDNASH in 2017 based on Gemcabene’s Lipid-Lowering and Inflammation Mechanism of Action

2017-01-05 : Phenex Pharmaceuticals AG Receives $100M Milestone Payment From Gilead (GILD)

2017-01-03 : Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

2016-12-19 : Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan

2016-12-16 : Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

2016-12-07 : NASH DeMili Test is online (http://www.demilitest.com)

2016-11-14 : Genfit initiates paediatric NAFLD/NASH program in Europe

2016-11-14 : Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016

2016-11-02 : Gilead stated that no further development of simtuzumab will be pursued

2016-09-27 : GENFIT is Filing for IND Submission for New Indication of Elafibranor in Primary Biliary Cholangitis (PBC)

2016-09-25 : GALECTIN Ph2a NASH FX TRIAL FAIL ! STILL IN THE RACE WITH ONGOING NASH CX TRIAL

2016-09-20 : GENFIT: Significant Milestones Achieved under a New Qualification Program of Proprietary miRNAs and Algorithms for a Non-invasive NASH Diagnostic

2016-09-20 : Allergan buy TOBIRA for 1.7 billion $

2016-08-22 : Avolynt, Inc. Announces FDA Acceptance of IND to Commence Pivotal Trial of Remogliflozin for NASH

2016-08-20 : The NAFLD induced cost in 5 country (USA,UK,Italy,Germany, France) is close to 140 Billon $

2016-08-02 : Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis

2016-07-29 : Shire receives FDA Fast Track for Volixibat on NASH with fibrosis

2016-07-14 : Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year

2016-04-21 : The full publication of GENFIT GOLDEN results are Published in Gastroenterology

2016-04-21 : A very good overview on NASH and PBC trials by Mary E. Rinella

2016-04-12 : Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

2016-04-04 : GILEAD Announces Aquisition of Nimbus Therapeutic -Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases -

2016-03-30 : Aramchol™ Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease

2016-01-15 : Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

2015-10-29 : OCA fails to meet primary endpoint in Japanese patients with NASH

2014-08-24 : Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A)








You want to join a clinical trial on NASH

Click on Sam


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE